Nalaganje...
ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE
BACKGROUND: Combination therapy is an emerging concept to improve the clinical effects of oncolytic virus based anti-cancer strategies. In a phase I/IIa trial (ParvOryx01) the oncolytic H-1 parvovirus (H-1PV) induced markers of immune activation in patients with recurrent glioblastoma. The goal of t...
Shranjeno v:
| izdano v: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216150/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.035 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|